Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
Date:7/27/2011

NANJING, China, July 27, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2011 on Tuesday, August 9, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, August 9 at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:United States toll-free:+1.866.510.0708International:

+1.617.597.5377China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:

10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)

400.881.1630 / 400.881.1629Hong Kong:

+852.3002.1672Please ask to be connected to Q2 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 72942369.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.888.286.8010International:

+1.617.801.6888The passcode for replay participants is 99140552. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:Yehong Zhang

President

Simcere Pharmaceutical GroupTel: 86-25-8556-6666 ext 8811In the United States:Cindy Zheng

Brunswick Group

Tel: 1-212-333-3810In Beijing:Yue Yu

Brunswick Group

Tel: 86-10-5960-8600In Hong Kong:Joseph Lo Chi-Lun

Brunswick Group

Tel: 852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
2. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
3. Simcere Announces Recent Progress of Qiangkes Registration
4. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
5. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
6. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
7. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
8. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
9. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
10. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
11. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology:
(Date:2/13/2016)... Angeles, California (PRWEB) , ... February 13, 2016 , ... ... help landing a date for the big day. A great outfit, flawless hair, and ... ashtray, they might as well resign themselves to a night at home with Rover. ...
(Date:2/13/2016)... Viejo, CA (PRWEB) , ... February 13, 2016 , ... ... ember particle overlays to footage all within Final Cut Pro X. Each user can ... control over 3D rotation, angle of view, blur, focus offset, hue, saturation, value, contrast, ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
Breaking Medicine News(10 mins):